272 related articles for article (PubMed ID: 17367921)
1. Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
Dutta PR; Maity A
Cancer Lett; 2007 Sep; 254(2):165-77. PubMed ID: 17367921
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
4. Review of epidermal growth factor receptor biology.
Herbst RS
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):21-6. PubMed ID: 15142631
[TBL] [Abstract][Full Text] [Related]
5. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
6. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.
Ritter CA; Arteaga CL
Semin Oncol; 2003 Feb; 30(1 Suppl 1):3-11. PubMed ID: 12644979
[TBL] [Abstract][Full Text] [Related]
7. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor targeting in cancer.
Mendelsohn J; Baselga J
Semin Oncol; 2006 Aug; 33(4):369-85. PubMed ID: 16890793
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
[TBL] [Abstract][Full Text] [Related]
10. EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Quatrale AE; Porcelli L; Silvestris N; Colucci G; Angelo A; Azzariti A
Front Biosci (Landmark Ed); 2011 Jan; 16(5):1962-72. PubMed ID: 21196276
[TBL] [Abstract][Full Text] [Related]
11. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
[TBL] [Abstract][Full Text] [Related]
12. Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
Bianco R; Troiani T; Tortora G; Ciardiello F
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
[TBL] [Abstract][Full Text] [Related]
14. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
15. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
16. Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
Harari PM; Huang S
Semin Radiat Oncol; 2006 Jan; 16(1):38-44. PubMed ID: 16378905
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor signaling in nonsmall cell lung cancer.
Ganti AK
Cancer Invest; 2010 Jun; 28(5):515-25. PubMed ID: 20073576
[TBL] [Abstract][Full Text] [Related]
18. Development of strategies for the use of anti-growth factor treatments.
Jones HE; Gee JM; Taylor KM; Barrow D; Williams HD; Rubini M; Nicholson RI
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S173-82. PubMed ID: 16113094
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
20. Emerging combination therapies to overcome resistance in EGFR-driven tumors.
Ratti M; Tomasello G
Anticancer Drugs; 2014 Feb; 25(2):127-39. PubMed ID: 24113593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]